In breve
Questo articolo riassume i trial clinici su Roxadustat. Gli studi valutano sicurezza, attività ed efficacia in popolazioni diverse, tra cui bambini e adolescenti con anemia da malattia renale cronica e adulti con fattori di rischio cardiovascolare e sindrome metabolica.
Punti chiave
- Roxadustat is being studied in Phase 3 clinical trials for two different patient groups. One trial looks at children and adolescents with anemia linked to chronic kidney disease, while another looks at people with cardiovascular risk factors and metabolic syndrome. The pediatric study measures change in hemoglobin over a 24-week treatment period. The cardiometabolism study measures plasma total cholesterol levels and also examines glucose and lipid metabolism and cardiovascular function. Both studies are authorised and are designed to learn more about activity, safety, and efficacy in the groups being studied.
Clinical trials overview
These clinical trials are studying Roxadustat in different patient groups and for different health problems. Both studies are Phase 3 and are listed as Authorised. One trial focuses on anemia in children and adolescents with chronic kidney disease, and the other focuses on cardiometabolic risk in people with cardiovascular disease risk factors and metabolic syndrome.
Pediatric study in chronic kidney disease
The pediatric study is an open-label, uncontrolled Phase 3 trial for participants with anemia associated with chronic kidney disease. It includes children and adolescents, and the brief summary says the goal is to evaluate the activity of Roxadustat for treating anemia in this group.
This trial plans to enroll 104 participants. The main outcome is the change in hemoglobin from the start of treatment to the average level during treatment weeks 20 to 24. The treatment period is described as 24 weeks, with 4 weeks of fixed dose treatment followed by 20 weeks of dose titration, which means the dose is adjusted over time.
Cardiometabolism study
The second trial is a Phase 3 interventional study called Effect of Roxadustat on Cardiometabolism. It studies people with risk factors of cardiovascular disease and metabolic syndrome. The brief summary says the study is looking at the effects of Roxadustat on glucose and lipid metabolism and on cardiovascular function.
This study plans to enroll 24 participants. Its primary outcome is plasma total cholesterol levels. The intervention list includes placebo and Roxadustat, which shows that the study is comparing treatment conditions.
Study design and main measures
Both trials are designed to measure specific results, called endpoints, so researchers can judge the effect of Roxadustat in each study population. In the pediatric trial, the key endpoint is hemoglobin change, which helps show whether anemia is improving. In the cardiometabolism trial, the key endpoint is total cholesterol in plasma, which helps show changes in blood fat levels.
The trial data also show different study styles. One study is open-label and uncontrolled, while the other includes placebo, so the research designs are not the same.
Who the trials are for
The pediatric trial is for children and adolescents with anemia linked to chronic kidney disease. The cardiometabolism trial is for people with cardiovascular risk factors and metabolic syndrome. These groups are different, so the studies are not asking the same question in the same type of patient.
- Children and adolescents with chronic kidney disease: this group is studied to see whether Roxadustat helps anemia improve over time.
- People with cardiometabolic risk: this group is studied to see whether Roxadustat affects cholesterol, glucose and lipid metabolism, and cardiovascular function.
Key terms explained
Chronic kidney disease means a long-term kidney problem. Anemia means the blood has too little hemoglobin, so it may carry less oxygen. Metabolic syndrome is a group of health problems that raise the risk of heart disease and diabetes. Cardiovascular function refers to how the heart and blood vessels work.